| 产品描述: | PLK1 选择性抑制剂;PLK1 Selective Inhibitors;产品介绍:Onvansertib (NMS-P937, PCM-075, NMS1286937)是一种口服有效的,选择性的 Polo-like Kinase 1 (PLK1) 抑制剂,其IC50值为2 nM,比PLK2/PLK3高出5000倍的选择性。Onvansertib (NMS-P937) 可在肿瘤细胞系中造成有丝分裂周期阻滞及凋亡并抑制肿瘤生长。;InformationOnvansertib (NMS-P937, PCM-075, NMS1286937) is an orally available, selectivePolo-like Kinase 1 (PLK1)inhibitor withIC50of 2 nM, 5000-fold selectivity over PLK2/PLK3. Onvansertib (NMS-P937) potently causes a mitotic cell-cycle arrest followed byapoptosisin cancer cell lines and inhibits tumor growth. Phase 1.TargetsPLK1 2 nMIn vitroNMS-P937 shows a broad-spectrum antiproliferative activity against different solid tumor, leukemias and lymphomas cell lines. NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in A2780 cells.In vivoIn mice xenografted with human HCT116 colon adenocarcinoma cells, NMS-P937 (90 mg/kg/d i.v. or p.o.) shows a significant tumor growth inhibition. In mice bearing HT29, Colo205 colorectal, or A2780 ovarian xenograft tumors, NMS-P937 inhibits xenograft tumor growth. In addition, NMS-P937, in combination with approved cytotoxic drugs, causes enhanced tumor regression, and prolongs survival of animals.Cell Research(from reference)Cell lines:137 solid tumor cell lines, and 43 cell lines derived from leukemias and lymphomas Concentrations:~10 μM Incubation Time:72 hours |